MUSC Hollings Cancer Center

Michael B. Lilly, MD

NOTED RESEARCHER AND UROLOGIC ONCOLOGIST MICHAEL B. LILLY, MD, JOINS HOLLINGS CANCER CENTER TO CO-LEAD TRANSLATIONAL RESEARCH PROGRAM

May 1, 2012, Charleston, SCMichael B. Lilly, MD, a noted translational cancer researcher and urologic oncologist, has joined the Hollings Cancer Center at the Medical University of South Carolina to co-lead the cancer center’s translational research program.  Dr.  Lilly will also see patients with advanced prostate cancer at Hollings and the Ralph H. Johnson VA Medical Center.

Lilly is a recognized expert in the field of targeted therapeutics.  Specifically, he has focused on stress response pathways that are triggered in cancer cells and which contribute to resistance to cancer therapy.  Many stresses (including the stresses generated by cancer treatment) lead cells to activate defense pathways that allow them to survive the stress. 

“We are so fortunate to have a physician-scientist of Dr. Lilly’s caliber join the MUSC faculty,” said Hollings Cancer Center Director Andrew S. Kraft, MD. “He joins Hollings at an exciting time, and I can’t think of anyone better to help foster collaborations between laboratory scientists and clinicians.”

Lilly holds significant funding from the US Department of Defense and the biotech industry. His lab will establish Hollings as the headquarters of a nationwide consortium to carry out a clinical trial in men with castration-resistant prostate cancer previously treated with chemotherapy.  His team, in collaboration with UCLA, will work to identify additional ways of improving outcomes for those patients.

“The recognition of Hollings as a National Cancer Institute-designated center is a major accomplishment and places the institution in a small, elite group of institutions that share the confidence of the NCI,”
Lilly said. “I have been impressed with the tremendous energy and enthusiasm found here.  The partnership between MUSC and the state in supporting focused, high-profile recruitments and cancer research is a forward-looking strategy that is not found in many other places.” 

Dr. Lilly, a professor of Medicine, was recruited from the University of California, Irvine, where he most recently served as vice chief for Clinical Programs in the Division of Hematology/Oncology. He also served as co-leader for the Translational Oncology Program and the Prostate Translational Working Group. Prior to his tenure at the University of California, Irvine, Lilly spent eight years at the Loma Linda University School of Medicine where his leadership roles included director at the Center for Molecular Biology and Gene Therapy.

 
 
 

* This website is best viewed in Firefox or Chrome internet browsers.

 
You'll need Skype CreditFree via Skype